

Genoeconomics

*Daniel J. Benjamin, Christopher F. Chabris, Edward Glaeser, Vilmundur Gudnason,
Tamara B. Harris, David Laibson, Lenore Launer, and Shaun Purcell*

**Paper prepared for the Workshop on Collecting and Utilizing Biological Indicators
and Genetic Information in Social Science Surveys¹**

Draft: December 31, 2006

¹ This paper has benefited from suggestions made by the volume editors, two anonymous reviewers, and participants at the NAS Workshop on Collecting and Utilizing Biological Indicators and Genetic Information in Social Science Surveys. The authors acknowledge funding from the NIA.

INTRODUCTION

Since Taubman (1976), twin studies have identified a significant degree of heritability for income, education, and many other economic phenotypes (e.g., Behrman et al., 1980, Behrman and Taubman, 1989). These studies estimate heritability by contrasting the correlation of economic phenotypes in monozygotic (identical) twin pairs and dizygotic (fraternal) twin pairs. Recent improvements in the technology of studying the human genome will enable social scientists to expand the study of heritability, by incorporating molecular information about variation in individual genes. This essay describes our hopes and concerns about the new research frontier of economic genomics, or genoconomics.

The core theme of health economics is that individual behavior and social institutions influence health outcomes (Fuchs, 1974). The primary contribution of genoconomics will likely be to identify the many ways in which individual behavior and social institutions moderate or amplify genetic differences.

Within genoconomics, there will be at least three major types of conceptual contributions. First, economics can contribute a theoretical and empirical framework for understanding how market forces and behavioral responses mediate the influence of genetic factors. Second, incorporating genetics into economic analysis can help economists identify and measure important causal pathways (which may or may not be genetic). Finally, economics can aid in analyzing the policy issues raised by genetic information.

Smoking provides one example of economic analysis that can improve the study of how genetic variation influences phenotypic variation. Traditional heritability studies suggest at least some genetic component to lung cancer (Lichtenstein et al., 2000); molecular genetics identifies a locus of lung cancer susceptibility on chromosome 6q23-25 (Bailey-Wilson et al., 2004). The genetic susceptibility to lung cancer is undoubtedly amplified by cigarette smoking, an economic decision affected by advertising, social norms, cigarette prices, consumer income, and tax rates on cigarettes (Cutler and Glaeser, 2005). Economics can explain how social institutions – like the market for cigarettes -- interact with genes to jointly generate important health phenotypes like lung cancer. More generally, economic institutions may either reduce or amplify the inequalities produced by genetic variation. In some situations, social transfers partially offset genetic factors – for instance, when individuals with illness receive extra insurance-based resources to treat or manage their illness. On the other hand, social institutions sometimes heighten inequalities associated with genetic factors – for instance, when individuals with advantageous cognitive abilities receive *extra* “merit-based” resources in the form of academic scholarships and admission to college or post-graduate degree programs.

The second subfield uses genetic information to identify causal mechanisms. This subfield will recognize a central fact of empirical economics: the ubiquity of mutual causation – for instance, health influences wealth, and vice versa (Case, Lubotsky, and Paxson, 2002). Genetic measures can help to separate the causal effect in a particular direction. For example, a robust literature argues that height, even in adolescence, increases earnings (Persico et al., 2004). However, this literature is plagued by difficulty

in controlling for the fact that height also reflects better health and nutrition in wealthier families. If height-linked alleles were identified, then they could, in principle, be used to measure the causal impact of exogenous variation in height. More formally, such research would analyze allele variation across siblings to identify the causal effect of genetic predispositions for height (controlling for household background characteristics). To take another example, Ding et al. (2004) address the causal effect of health on educational outcomes, using genetic predictors of health to ameliorate confounding by third factors potentially correlated with both health and educational outcomes. More generally, cognition-linked alleles will contribute to our understanding of the cognitive factors that influence income, or the extent to which cognitive factors influence decision-making about savings and wealth. Genetic research will also identify biological mechanisms that interact with environmental factors to jointly influence behavior. We anticipate that crude concepts like “risk aversion” (unwillingness to take risks) and “patience” (willingness to delay gratification) that are central to economic analyses will be decomposed into much more useful subcomponents associated with particular neural mechanisms and their environmental and genetic antecedents (Plomin, Corley, Caspi, Fulker, and DeFries, 1998). Finally, ongoing research will eventually enable researchers to employ new genetic control variables, thereby improving the power of statistical procedures.

Much of the promise of genoeconomics is based in part on economists’ long tradition of policy analysis. The economic approach is one in which governments are not seen as infallible custodians of the public good, but rather as separate actors that often have their own objectives (Stigler, 1971). Information economics may also play an

important role in the analysis of policy questions. Economists have identified competitive forces that cause individuals to reveal information that is privately beneficial but potentially socially harmful. Economists understand how the public release of certain genetic information can theoretically undermine insurance institutions and thereby inefficiently increase social inequality. Genoeconomics will also identify specific gene-environment interactions with policy implications. For example, imagine that particular genes turn out to be risk factors for poor educational outcomes, poor performance in the labor market, and consequently low levels of income. Imagine too that particular educational interventions are found that mitigate these disadvantages. Then gene-based policies could target disadvantaged groups with focused interventions. Such interventions will remain purely speculative until the necessary precursor research is implemented and ethical questions are resolved, but focused interventions nevertheless hold out considerable long-run potential.

Despite the promise of genoeconomics, there are clearly enormous pitfalls. Even under the best of circumstances—when a particular genetic pathway has been clearly established—there are concerns about informing individuals of their own risks, especially when there are few interventions to alleviate those risks or when the risks are very small. Providing information to parents about the genome of a fetus or child creates a different set of dilemmas, including the risk of selective abortion. This has been well-discussed with reference to a genetic endowment as straightforward as gender, where in many societies economic investment in a daughter is seen as less beneficial than economic investment in a son (e.g., Garg and Morduch, 1998). If the same issues arose in relation to more complex economic traits, this would generate a host of ethical and policy

questions. Documenting the power of the genome to society at large also creates risks as identifiable social and ethnic groups may face discrimination (or become beneficiaries of positive discrimination) on the basis of their presumed genetic endowments.

These problems are multiplied when genetic research is done carelessly. Historically, there have been many cases of false positives where early genetic claims have evaporated under subsequent attempts at replication. These false positives can create tremendous mischief. A failure to highlight the full extent of the interaction between genes and environment is likewise dangerous because the public may come to believe falsely in genetic determinism. The responsible path requires statistical care, attention to how genes and environment jointly determine outcomes, and extreme sensitivity to the ethical issues surrounding genetic knowledge.

Despite these dangers, we believe that there is potential for productive collaboration between economists, cognitive scientists, epidemiologists and genetic researchers. In the rest of this essay, we sketch one vision for this field. In Section II, we discuss methodological challenges that confront research in genoeconomics. In Section III, we outline a study that is currently underway, which uses a SNP panel to analyze associations between candidate cognitive genes and economic phenotypes. Section IV concludes.

II. METHODOLOGICAL CHALLENGES AND PITFALLS

Successful implementation of the research program described above will require careful attention to many methodological issues, some of which we outline in this

section. A critical issue is the choice of economic phenotypes to study. Proximal behavioral phenotypes, such as impatience or risk-aversion, are probably more directly related to genetic propensities than more distal economic phenotypes, such as wealth accumulation or labor force participation.

Proximal phenotypes have typically been measured with personality tests. Some personality systems are purely conceptually based (e.g., the five factor model) while others are rooted in neurobiology (e.g., Cloninger's three dimensions tied to the dopamine, serotonin, and norepinephrine systems; Cloninger, 1987; Cloninger et al., 1993). Recently some personality attributes have been studied with neuroimaging (e.g., Hariri 2006).

Distal phenotypes -- for instance wealth accumulated over a lifetime -- may also strongly reflect genetic influences because they represent the cumulative effect of many specific decisions, and may reflect the expression of genes over a long period of time. Given the current state of knowledge (especially the relative lack of definitive findings relating traditional personality traits to specific genetic polymorphisms; see Ebstein, 2006; Munafo et al., 2003), the wisest course is probably to measure both proximal and distal phenotypes, and to investigate how the proximal phenotypes mediate the relationship between genes and more distal phenotypes.

In the rest of this section, we focus on gene-environment interaction studies in the context of quantitative genetic designs and modern association analysis. In that setting we consider issues under three general headings: the non-independence of genes and environments; the measurement of genetic variation; and problems searching for small, complex effects.

Correlated Genes and Environments

Genes and environments are, for various reasons, often not independent factors. This has implications for statistical designs attempting to uncover genetic influences, environmental influences, and interactions of genes and environments.

Gene-environment interaction (GxE) can be conceptualized as the genetic control of *sensitivity* to different environments. In contrast, a correlation between genes and environment (GE correlation, rGE) can represent genetic control of *exposure* to different environments (Kendler, 1986; Plomin and Bergeman, 1991). For example, Jang et al. (2000) show that genetic influences on alcohol and drug misuse are correlated with various aspects of the family and school environment.

We might expect correlations between genes and environments to arise for a number of reasons. For example, individuals do, to some extent, implicitly select their own environments on the basis of innate, genetically-influenced characteristics.

One important form of gene-environment correlation arises due to population stratification. A stratified sample is one which contains individuals from two or more subpopulations which may differ in allele frequencies at many sites across the genome. This will induce a correlation in the sample between all allelic variants that differ in frequency between the subpopulations and any environmental factors, diseases, or other measures that also happen to differ (possibly for entirely non-genetic reasons) between the subpopulations. As such, population stratification is an important source of potential confounding in population-based genetic studies. For example, if cases and controls are

not matched for ethnic background, population stratification effects can lead to spurious association, or false-positive errors. To address concerns over possible hidden stratification effects, a series of family-based tests of association have been developed. Because related family members necessarily belong to the same population stratum, using relatives as controls automatically ensures protection against the effects of stratification (Spielman et al., 1993). Recently, a different approach—called genomic control, or structured association—has emerged, directly using DNA markers from across the genome to directly infer ancestry for individuals in the sample or to look for signs of stratification (Devlin & Roeder, 1999; Pritchard et al., 2000).

An association between an environment and an outcome may arise due to a third variable, namely common genetic inheritance (e.g., DiLalla and Gottesman 1991). For example, if a gene X is inherited, it might cause phenotypes Y and Z respectively in a parent and in a child. Researchers will observe a correlation between the parental phenotype Y and the child's phenotype Z. Researchers may mistakenly infer a causal relationship between Y and Z if they do not control for the real (unobserved) causal mechanism: gene X.

Measuring Genetic Variation

The typical “gene by environment” association study should really be called an “allele by environment” study because, very often, only a single variant within a gene is studied. In the context of standard candidate gene association studies, many researchers are realizing that failure to comprehensively measure all common variation in a gene or

184 region can lead to inconsistent results and makes the interpretation of negative results
185 particularly troublesome. (If you have not adequately measured “G,” then it is hard to
186 evaluate its relationship to the phenotype.) With emerging genomic technologies, it will
187 soon be easy to measure myriad single nucleotide polymorphisms or microsatellite
188 markers, even if only one SNP is known to be functional.

189 The same issue applies to GxE analysis. The question will be how to adapt GxE
190 methods to this new “gene-based” paradigm, in which the gene rather than the specific
191 allele, genotype or haplotype becomes the central unit of analysis. In addition, if a
192 researcher measures multiple genes (for example, all genes in a pathway, each with
193 multiple markers), then new analytic approaches will be needed to simultaneously model
194 the joint action of the pathway, as well as how the individual genes influence the
195 phenotype or interact with the environment.

196 Naturally, more comprehensively measuring all common variation in a gene costs
197 more both financially (more genotyping) and statistically (more tests are performed).
198 How to best combine information from multiple markers in a given region is an ongoing
199 issue in statistical genetics. One option is to simply test each variant individually and
200 then adjust the significance levels to account for this multiple testing. Standard
201 procedures such as the Bonferroni are typically too conservative because they assume the
202 tests are independent. Instead, it is often better to use permutation procedures to control
203 the family-wise error rate or to control the false discovery rate (FDR). A second option is
204 to combine the single variants together, either in a multilocus test (such as Hotelling’s T^2
205 or a set-based test using sum-statistics), or in a haplotype-based test. As mentioned
206 above, this is currently a very active area of research (e.g., Brookes et al., 2006).

Unfortunately, all these approaches rely on the variation being common. Even for large samples, this means that variants with a population frequency of less than 1% are unlikely to be detected. If a gene is important for a given outcome but contains multiple, different rare variants, then many current approaches will fail.

Searching for Small Effects and Interactions

Increasingly, researchers are appreciating the central importance of large sample sizes in genetics to afford sufficient statistical power to detect small effects. For complex, multifactorial traits, many researchers expect the effects of individual variants to be as low as <1% of the total phenotypic variance for quantitative outcomes. For case/control designs, allelic odds ratios of 1.2 and lower are often considered. Such small effects require very large samples—typically thousands of individuals, if more than one variant is to be tested and proper controls for multiple testing are in place. The consequences of chronic low statistical power are sobering. If power is on average only marginally greater than the Type I error rate, then a large number of published studies may well be Type I errors. Average power around the 50% level yields a pattern of inconsistent replication. Unfortunately, a great deal of time and money has been spent on poorly designed experiments that, at best, stand little chance of doing what they are supposed to, and, at worst, are advancing Type I errors in the literature.

Although the individual effects of any one variant may be very small, it is of course a possibility that this is because they represent the marginal effect of an interaction, for example with some environmental factor. In other words, by looking only

at a single variant and essentially averaging over all other interacting environmental factors, one would only see an attenuated signal and perhaps miss the link between the gene, environment and outcome. This is one reason for explicitly considering G×E when searching for genetic variants.

In humans, G×E has been found in monogenic diseases; in plant and animal genetics, there is strong evidence for G×E in complex phenotypes. For example, phenylketonuria is a Mendelian human disorder, but the gene only acts to produce the severe symptoms of mental retardation in the presence of dietary phenylalanine. Research in *Drosophila melanogaster* has found evidence for G×E in quantitative traits including bristle number, longevity and wing shape (Mackay, 2001; Clare and Luckinbill, 1985). The detection of G×E in model organisms suggests that it will play an equally important role in complex human phenotypes. Indeed, promising results are emerging (e.g., Caspi et al., 2002, 2003; Mucci et al., 2001; MacDonald et al., 2002; Dick et al., 2006). However, human studies suffer from a crucial methodological difference: the inability to inexpensively experimentally manipulate genes and environments. Epidemiological designs will therefore tend to be less powerful, as well as prone to confounding. Despite these greater challenges, consideration of G×E in human molecular genetic studies potentially offers a number of rewards, including increased power to map genes, to identify high-risk individuals, and to elucidate biological pathways.

Many commentators have noted the general difficulties faced in uncovering interactions of any kind (e.g., Clayton and McKeigue, 2001; Cooper, 2003). Indeed, general epidemiology has struggled for decades to adequately define and test interaction.

The central problem, as stated by Fisher and Mackenzie in 1923 when first describing the factorial design and analysis of variance (ANOVA), is that, in statistical terms, “interaction” is simply whatever is left over after the main effects are removed. It follows that the presence or absence of interaction can depend on how the main effects are defined. For dichotomous phenotypes, the presence of a measured interaction effect will depend on the modeling assumption that is used in the empirical analysis (see Campbell et al., 2005, for another example). For example, if the risk genotype G+ has (likelihood ratio) effect g and the risk environment E+ has (likelihood ratio) effect e , the question is how to specify the joint effect *in the absence of an interaction*. Assuming an additive model implies that the joint effect (without an interaction effect) is $g+e-1$ whereas a multiplicative model implies that the joint effect (without an interaction effect) is ge . Hence, the absence of an interaction effect in the additive model generically implies the existence of an interaction effect in the multiplicative model (and vice versa). Mathematically, as long as neither g nor e is equal to one, then, $g + e - 1 \neq ge$.

Analogously, for quantitative phenotypes, transformation of scale can induce or remove interaction effects. To see this, imagine a G×E study of amygdala morphology (i.e., measures of the anatomical size of the amygdala based on magnetic resonance images). For illustrative purposes, assume that the amygdala is a sphere with radius given by an additive sum of a gene effect -- 1mm -- and an environment effect -- also 1mm. Assume too that the radius exhibits no gene-environment interaction.

[INSERT FIGURE 1 HERE.]

FIGURE 1 Measurement of G×E depends on the modality of measurement

277	Radius (mm)		E-	E+
278		G-	1	2
279		G+	2	3
280				
281	Area/ π (mm ²)		E-	E+
282		G-	1	4
283		G+	4	9
284				
285				
286	Volume $\cdot 3/(4\pi)$ (mm ³)		E-	E+
287		G-	1	8
288		G+	8	27
289				

290

291

292 If the measured phenotype were cross-sectional area (a function of radius
293 squared), however, gene and environment are no longer additive in their effects. There is
294 now $G \times E$, as $G+$ increases area by 3 units under $E-$ and 5 units under $E+$. If the
295 phenotype were based on volume, the apparent measurement of $G \times E$ is stronger.
296 However, these interaction effects are purely “statistical” and not “biological”: that is, G
297 and E do not interact on any causal level. The interactions are effectively a consequence
298 of misspecifying the main effects model (see Figure 1).

299 Consider now that a “downstream” phenotype is measured, such as some aspect
300 of the serotonergic system that is influenced by the amygdala. There can be no guarantee
301 that the effects of G and E should necessarily display an additive relationship at this level,
302 considering the various neurochemical cascades and reciprocal feedback loops that are
303 presumably involved in a system as complex as the human brain. Or the measured
304 phenotype may be even further downstream—a clinical diagnosis based on behavioral
305 symptoms, or a 25-item self-report questionnaire measure, log-transformed to

306 approximate normality. Finding $G \times E$ at these levels may well be strikingly irrelevant
307 with respect to the presence of interaction at the causal level.

308 The point of this example is not to claim that the only appropriate causal level is
309 the neurological one. Rather, for complex phenotypes, the level at which genes and
310 environment operate (which need not be the same level) might often be quite distal
311 compared to the level of measured phenotype. Consequently, the distinction between
312 statistical and biological interaction always should be borne in mind. Purely statistical
313 interactions are still useful if one's only goal is prediction, e.g., early diagnosis or
314 identification of high risk individuals. But to help understand mechanisms and pathways,
315 an interaction detected by statistical methods must have some causal, biological or
316 behavioral counterpart to be of significant interest.

317 False negatives are also a major concern in the study of $G \times E$. Tests of interaction
318 generally suffer from relatively low power (Wahlsten, 1990). In this case, it is not clear
319 that efforts to detect genes will benefit from more complex models that allow for
320 potential $G \times E$ effects, even if $G \times E$ effects are large.

321 Nature is undoubtedly complex. How complex our statistical models need to be is
322 less clear. Combining the definitional problems of interaction with the low power to
323 detect $G \times E$ with the new avenues for multiple-testing abuses brought about by extra E
324 variables, attempting to incorporate $G \times E$ could make an already difficult endeavor near
325 impossible (Cooper, 2003). However, we see these obstacles as important but not
326 insurmountable: with proper experimental design and better-developed statistical tools,
327 $G \times E$ will be able to be robustly detected, with relevance to biology, public health, and
328 eventually economics.

Although larger datasets—more individuals, more phenotypic measures, more genetic variants assayed—are desirable for many reasons (some of which have already been mentioned), they also pose a further methodological challenge for detecting G×E. A new wave of whole genome scale studies has already begun, in which as many as half a million single nucleotide polymorphisms (SNPs) are assayed. Issues of multiple testing and statistical power are already paramount in such studies. Efforts to detect G×E magnify these concerns.

III. THE AGES-REYKJAVIK STUDY COLLABORATION

Currently, the main obstacle to bringing genetic research into economics is the fact that few datasets combine economic measures with biosamples that can be genotyped. An exception is the Age, Gene/Environment Susceptibility-Reykjavik Study. In this section, we describe a project where we have begun using these data to explore associations between genes that are candidates for involvement in decision-making and economic phenotypes, and how these relationships are mediated by the environment. We believe our project illustrates one possible direction for research in economic genomics, as well as some of the benefits of multidisciplinary collaboration—including team members with training in economics, cognitive science, epidemiology, medicine, genetics, and statistics.

Administered by the Icelandic Heart Association, the original Reykjavik Study (RS) surveyed 30,795 men and women born between 1907 and 1935 who lived in Reykjavik as of 1967. While the majority of participants were surveyed once between

1967 and 1991, about 5,700 were surveyed twice and about 6,000 were surveyed six times over this period. The Older Persons Exam, which contained many components of the RS questionnaire as well as additional health measures, was administered between 1991 and 1997 to all living participants aged 70 and older as of 1991. The Laboratory of Epidemiology, Demography, and Biometry initiated the Age, Gene/Environment Susceptibility (AGES) Study in 2002 in collaboration with the Icelandic Heart Association to collect genotypic as well as additional phenotypic data from 5764 of the 11,549 surviving participants. Currently, 2,300 participants have been genotyped. Hereafter, we refer to the combined dataset as the “Icelandic data.” For more detailed information about the Icelandic data, see Harris et al. (2007).

Although primarily used to study health, the Icelandic data already contain a number of measures of economic interest, summarized in Table 1. Distal economic phenotypes we plan to study include labor supply and wealth accumulation. For example, Figure 1 shows the percentage of respondents who have a second job. Figure 2 shows the distribution of working hours in the sample. Notice that there is a substantial amount of variation in these phenotypes. The RS questionnaire asks about attributes of participants’ house or apartment, from which it is possible to construct a proxy measure of housing wealth. We are currently investigating the feasibility of collecting more extensive measures of wealth and income.

In addition to these distal phenotypes, we plan to study proximal phenotypes—such as impulsiveness, risk-aversion, and cognitive ability—that may be more closely related to underlying genetic propensities. A measure of general cognitive ability can be constructed from existing data on long-term memory, speed of processing, and working

memory. Various questionnaires ask about health-related decisions, such as smoking, drinking, eating habits, and conscientious health behaviors (e.g., getting regular check-ups). Each of these decisions reflects a tradeoff between the present and the future, and economic theory postulates that some individuals are more impulsive, or “impatient” in economics jargon. From these decisions, we will construct an index of impulsive behaviors.

We also plan to add standard experimental measures of impulsive and risk-averse preferences to the next wave of the AGES-Reykjavik study. These protocols ask participants to choose between immediate vs delayed monetary rewards or to choose between certain vs risky monetary rewards. These choices are played out with real monetary stakes. Such measures correlate with real-world impulsive and risky decisions across a range of contexts (e.g., for discounting: Fuchs, 1982; Bickel, Odum, and Madden, 1999; Petry and Casarella, 1999; Kirby, Petry, and Bickel, 1999; Kirby and Petry, 2004; Ashraf, Karlan, and Yin, 2004; Shapiro, 2005; for risk-aversion: Barsky et al., 1997; Dohmen et al., 2005; Kimball, Sahm, and Shapiro, 2006). These experimental measures yield similar distributions of responses whether they are administered to neurologically-healthy older adults or to college-age subjects (Kovalchik et al., 2003).

Existing research in economics implies that distal phenotypes, such as labor supply and wealth accumulation, will be related to proximal phenotypes that matter for decision-making such as impulsiveness, risk aversion, and cognitive ability (Barsky et al., 1997; Dohmen et al., 2005; Benjamin et al., 2006). These proximal phenotypes are more likely to be directly associated with underlying genetic propensities and to mediate the relationship between genetic polymorphisms and the distal phenotypes.

Three key empirical findings have motivated our choice of candidate genes for decision-making:

1. Research in the new field of neuroeconomics (Glimcher and Rustichini, 2004; Glimcher et al., 2005) has begun to explore the neuroscientific foundations of economic behavior.² McClure et al (2004) find that impulsive behavior, when measured with laboratory tasks, appears to be governed by the interaction between the brain's impatient "limbic system" (more accurately, mesolimbic dopaminergic reward-related regions) and a patient "cortical system" that includes elements of the prefrontal cortex and the parietal cortex. McClure et al. (2004) show that the limbic system is only active when individuals are confronted with choices between immediate and future rewards. By contrast, the cortical system is active for all decisions (whether or not immediate rewards are among the choices), and its activity increases on trials when subjects choose more delayed rewards.

2. Individual differences in the tendency to make impulsive, present-oriented decisions are associated with cognitive ability: high-ability individuals are less impulsive and more risk-neutral across a variety of decision-making domains, in both laboratory situations and real-world measures (Benjamin et al., 2006; see also Frederick, 2005), including financial choices, health behaviors, capital

² There is also a related, older literature that explores the relationship between personality and neuropharmacological interventions – for instance see Nelson and Cloninger (1997).

accumulation, and the like. Critically, this holds true even when controls for income are included.

3. Differences in cognitive ability, in turn, are mediated predominantly by structural and functional differences in prefrontal and parietal brain regions — the same network of cortical regions that functions to counter the impulsive tendencies of the limbic/reward system (Gray, Chabris, and Braver, 2003; Chabris, in press). General intelligence is also positively related to total brain volume (for a meta-analysis, see McDaniel, 2005).

These results lead us to the working hypothesis that prefrontal/parietal and limbic networks are the neural substrates of the psychological constructs of impulsiveness and cognitive ability (that are in turn related to economic decision-making). We therefore hypothesize that genes implicated in these traits and brain systems may be associated with economic behavior and outcomes in the Icelandic data. We have developed a list of these genes and their known or likely functional SNPs. Table 2 lists these genes. A SNP panel will be created for use with Illumina technology to rapidly genotype all 2300 subjects who have provided DNA in the Icelandic data. These SNPs will include both functional alleles and SNPs to tag haplotypes of the genes, based on the HapMap.

To select genes for this SNP panel, we focused on specific phenotypes and biological pathways of relevance to the model sketched above. First, we selected genes in two critical neurotransmission pathways, the serotonin and dopamine systems, because both of these pathways have been associated with impulsive behavior. (It is true that

442 these systems are not *exclusively* involved in impulsiveness, or decision-making in
443 general — all genetic or neurobiological systems, including the putative “language gene”
444 FOXP2, are involved in multiple cognitive and behavioral domains — but these provide a
445 useful starting points given the current state of knowledge about the neurobiology of
446 decision-making.) Serotonin function has been associated with several aspects of
447 impulsivity, including reward sensitivity and inhibitory cognitive control (e.g., Cools et
448 al., 2005; Walderhaug et al., 2002), as well as prefrontal cortex activity (Rubia et al.,
449 2005), while several dopamine-related genes have been associated with attention-deficit
450 hyperactivity disorder (ADHD; see Faraone et al., 2005 for a meta-analysis of association
451 studies) and with limbic/reward system functioning. Second, we selected genes that have
452 been associated or implicated in phenotypes related to cognitive ability: general
453 intelligence (i.e., IQ; Plomin, 1999; Plomin et al., in press); memory (e.g., de Quervain
454 and Papassotiropoulos, 2006); schizophrenia, which involves neurocognitive dysfunction
455 (Hallmayer et al., 2005); Alzheimer’s Disease; and brain size, which is positively related
456 to general cognitive ability (for a meta-analysis, see McDaniel, 2005; for candidate
457 genes, see Gilbert et al., 2005; Woods et al., 2005). Finally, we added several genes
458 associated with specific cognitive abilities such as memory and attention, or that are
459 linked to cognition via other mechanisms (Goldberg & Weinberger, 2004). Naturally,
460 there is overlap among these categories; for example, COMT (catechol-O-
461 methyltransferase) is part of the dopamine pathway, and it also has a common SNP that is
462 associated with measures of executive function and frontal lobe activation (Egan et al.,
463 2001); HTR2A (serotonin receptor 2A) is a serotonin receptor gene that has been
464 associated with long-term memory ability (de Quervain et al., 2003); and while HTT

465 (serotonin transporter) is a part of the serotonin system, it has also been associated with
466 ADHD and cognitive ability. Table 2 is therefore not meant to be an exhaustive or final
467 list of possible candidate genes for economic behavior, but rather our estimate of the best
468 starting points for study, given the literature published through the end of 2006.

469 In addition to the considerable behavioral and medical phenotypes, the Icelandic
470 data includes several measures of cognitive ability: speed of processing, working
471 memory, and long-term memory, as well as educational achievement, the mini-mental
472 state exam, and a clinical dementia evaluation. An index of general cognitive ability (g)
473 can be inferred from a principal components analysis of the individual cognitive tests;
474 indeed, working memory and processing speed are prominent components of g (Chabris,
475 2007). Each subject in the AGES follow-up also received structural magnetic resonance
476 imaging (MRI) of the brain with evaluations of atrophy, infarcts, white matter lesions,
477 and high-resolution T1-weighted images for voxel-based morphometric analysis.

478 We plan to examine direct associations between the genes in our SNP panel and
479 the distal economic outcomes measured in the Icelandic data – for instance, labor force
480 participation and housing wealth. We will also investigate whether these associations are
481 mediated by proximal variables like cognitive ability, brain morphology, and impatience.

482 To implement these analyses, we will construct composite phenotypic measures.
483 Such composites will reduce measurement error, increase power, and reduce the number
484 of statistical tests. Moreover, rather than simply testing each SNP genotype individually,
485 we will construct composite “SNP sets” that index the “load” of sets of SNPs that
486 individually may have small effects but collectively explain more variance in an outcome
487 measure (for examples of this methodology, see Harlaar et al., 2005, for general cognitive

ability; de Quervain and Papassotiropoulos, 2006, for memory; and Comings et al., 2002, for pathological gambling behavior).

IV. CONCLUSIONS

This essay reviews our hopes and concerns about the joint study of genetic variation and variation in economic phenotypes. The new field of genoeconomics will study the ways in which genetic variation interacts with social institutions and individual behavior to jointly influence economic outcomes.

Genetic research and economic research will have three major points of contact. First, economics can contribute a theoretical and empirical framework for understanding how individual behavior and economic markets mediate the influence of genetic factors. Second, incorporating (exogenous) genetic variation into empirical analysis can help economists identify and measure causal pathways and mechanisms that produce individual differences. Finally, economics can aid in analyzing the policy issues raised by the existence of genetic knowledge and its potential societal diffusion.

Despite the promise of genoeconomics, there are numerous pitfalls. Ethical issues crop up at every juncture, both during the research process and once the research results are disseminated. The problems are even greater when genetic research is done carelessly or reported misleadingly. Historically, there have been many cases of false positives in which preliminary genetic claims have subsequently collapsed as a result of unsuccessful replications. Communication about research results must also highlight the fact that genes alone do not determine outcomes. A highly complex set of gene effects,

511 environment effects, and gene-environment interactions jointly cause phenotypic
512 variation.

513 The way forward requires statistical care, attention to how the environment
514 mediates genes, and sensitivity to the ethical issues surrounding genetic knowledge. We
515 believe that there is potential for productive collaboration between economists, cognitive
516 scientists, epidemiologists, and genetic researchers. Indeed, we end the paper by
517 summarizing a study that is currently underway, which uses a SNP panel to analyze
518 associations between candidate cognitive genes and economic phenotypes.

REFERENCES

Formatted: English (U.S.)

- Ashraf N., Karlan D.S., Yin W. (2004). "Tying Odysseus to the mast: Evidence from a
commit savings project in the Phillipines." *Quarterly Journal of Economics*, 121(2):
635-672.
- Bailey-Wilson JE, Amos CI, Pinney SM., Petersen GM., de Andrade M, Wiest JS, Fain P,
Schwartz AG, You M, Franklin W, Klein C, Gazdar A, Rothschild H, Mandal D,
Coons T, Slusser J, Lee J, Gaba C, Kupert E, Perez A, Zhou X, Zeng D, Liu Q,
Zhang Q, Seminara D, Minna J, Anderson M (2004). "A major lung cancer
susceptibility locus maps to chromosome 6q23-25." *American Journal of Human
Genetics*, 75: 460-474.
- Barbaux S, Plomin R, Whitehead AS. (2000). "Polymorphisms of genes controlling
homocysteine/folate metabolism and cognitive function." *Neuroreport*, 11(5):1133-
1136.
- Barsky RB, Juster FT, Kimball MS, Shapiro MD. (1997). "Preference parameters and
behavioral heterogeneity: An experimental approach in the Health and Retirement
Study." *Quarterly Journal of Economics*, 112(2): 537-79.
- Barzilai N, Atzmon G, Derby CA, Bauman JM, Lipton RB. A genotype of exceptional
longevity is associated with preservation of cognitive function. *Neurology*. 2006 Dec
26;67(12):2170-5.

539 Behrman JR., Hrubec Z, Taubman P, Wales TJ. (1980). *Socioeconomic success: A study*
540 *of the effects of genetic endowments, family environment, and schooling*. New
541 York: North-Holland.

542 Behrman JR., Taubman P. (1989). "Is schooling 'mostly in the genes'? Nature-nurture
543 decomposition using data on relatives." *Journal of Political Economy*, 97: 1425–
544 1446.

545 Bendixen MH, Nexø BA, Bohr VA, Frederiksen H, McGue M, Kolvraa S, Christensen K.
546 (2004). "A polymorphic marker in the first intron of the Werner gene associates
547 with cognitive function in aged Danish twins." *Exp. Gerontol.*, 39(7):1101-1107.

548 Benjamin DJ, Brown SA, Shapiro, JM. (2006). "Who is 'behavioral'? Cognitive ability
549 and anomalous preferences." Submitted for publication.

550 Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of
551 Alzheimer disease genetic association studies: the AlzGene database. *Nat Genet.* 2007
552 Jan;39(1):17-23.

553 Bertram L, Tanzi RE. (2004). "Alzheimer's disease: one disorder, too many genes?" *Hum.*
554 *Mol. Genet.*, 13(1): R135-141.

555 Bickel WK, Odum AL, Madden GJ. (1999). "Impulsivity and cigarette smoking: Delay
556 discounting in current, never, and ex-smokers." *Psychopharm.*, 146(4): 447-454.

557 Blasi P, Palmerio F, Aiello A, Rocchi M, Malaspina P, Novelletto A. SSADH variation in
558 primates: intra- and interspecific data on a gene with a potential role in human
559 cognitive functions. *J Mol Evol.* 2006 Jul;63(1):54-68.

- 560 Bobb AJ, Addington AM, Sidransky E, Gornick MC, Lerch JP, Greenstein DK, Clasen
561 LS, Sharp WS, Inoff-Germain G, Wavrant-De Vrieze F, Arcos-Burgos M, Straub
562 RE, Hardy JA, Castellanos FX, Rapoport JL. (2005). "Support for association
563 between ADHD and two candidate genes: NET1 and DRD1." *Am. J. Med. Genet.*
564 *B. Neuropsychiatr. Genet.*, 134(1): 67-72.
- 565 Brookes KJ, Chen W, Xu X, Taylor E, Asherson P. Association of Fatty Acid Desaturase
566 Genes with Attention-Deficit/Hyperactivity Disorder. *Biol Psychiatry*. 2006 Aug 4;
567 [Epub ahead of print]
- 568 Burdick KE, Hodgkinson CA, Szeszko PR, Lencz T, Ekholm JM, Kane JM, Goldman D,
569 Malhotra AK. (2005). "DISC1 and neurocognitive function in schizophrenia."
570 *Neuroreport*, 16(12): 1399-1402.
- 571 Burdick KE, Lencz T, Funke B, Finn CT, Szeszko PR, Kane JM, Kucherlapati R,
572 Malhotra AK. (2006). "Genetic variation in DTNBP1 influences general cognitive
573 ability." *Hum. Mol. Genet.*, 15(10): 1563-1568.
- 574 Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR, Verchinski BA,
575 Meyer-Lindenberg A, Balkissoon R, Kolachana B, Goldberg TE, Weinberger DR.
576 (2005). "Variation in DISC1 affects hippocampal structure and function and
577 increases risk for schizophrenia." *Proc. Natl. Acad. Sci. U.S.A.*, 102(24): 8627-
578 8632.

579 Campbell UB, Gatto NM, Schwartz S. (2005) "Distributional interaction: Interpretational
580 problems when using incidence odds ratios to assess interaction." *Epidemiol*
581 *Perspect Innov.* 2(1):1.

582 Case A, Lubotsky D, and Paxson C. (2002). "Economic Status and Health in Childhood:
583 The Origins of the Gradient." *American Economic Review*, 92(5): 1308-1334.

584 Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, Taylor A, Poulton R. (2002).
585 "Role of genotype in the cycle of violence in maltreated children." *Science*,
586 297(5582): 851-854.

587 Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J,
588 Martin J, Braithwaite A, Poulton R. (2003). "Influence of life stress on depression:
589 moderation by a polymorphism in the 5-HTT gene." *Science*, 301(5631): 386-389.

590 Caspi A, Taylor A, Moffitt TE, Plomin R. (2000). "Neighborhood deprivation affects
591 children's mental health: environmental risks identified in a genetic design."
592 *Psychological Science*, 11(4): 338-342.

593 Chabris, C.F. (2007). "Cognitive and neurobiological mechanisms of the Law of General
594 Intelligence." In M.J. Roberts (Ed.), *Integrating the mind*. Hove, UK: Psychology
595 Press.

596 Chorney MJ, Chorney K, Seese N, Owen MJ, Daniels J, McGuffin P, Thompson LA,
597 Detterman DK, Benbow CP, Lubinski D, Eley TC, Plomin R. (1998). "A

598 quantitative trait locus (QTL) associated with cognitive ability in children.”
 599 *Psychological Science*, 9: 159-166.

600 Clare MJ, Luckinbill LS. (1985). “The effects of gene-environment interaction on the
 601 expression of longevity.” *Heredity*, 55(1), 19-26.

602 Clayton D, McKeigue PM. (2001). “Epidemiological methods for studying genes and
 603 environmental factors in complex diseases.” *Lancet*, 358: 1356-1360.

604 Cloninger CR. Neurogenetic adaptive mechanisms in alcoholism. *Science*. 1987 Apr
 605 24;236(4800):410-6.

606 Cloninger CR, Adolfsson R, Svrakic NM. Mapping genes for human personality. *Nat*
 607 *Genet*. 1996 Jan;12(1):3-4.

608 Comings DE, Gade-Andavolu R, Gonzalez N, Wu S, Muhleman D, Chen C, Koh P,
 609 Farwell K, Blake H, Dietz G, MacMurray JP, Lesieur HR, Rugle LJ, Rosenthal RJ.
 610 (2001). “The additive effect of neurotransmitter genes in pathological gambling.”
 611 *Clinical Genetics*, 60: 107-116.

612 Comings DE, Wu S, Rostamkhani M, McGue M, Lacono WG, Cheng LS, MacMurray
 613 JP. (2003). “Role of the cholinergic muscarinic 2 receptor (CHRM2) gene in
 614 cognition.” *Mol. Psychiatry*, 8(1):10-11.

615 Cools R, Blackwell A, Clark L, Menzies L, Cox S, Robbins TW. (2005). “Tryptophan
 616 depletion disrupts the motivational guidance of goal-directed behavior as a function
 617 of trait impulsivity.” *Neuropsychopharmacology*, 30: 1362-1373.

618 Cooper, RS. (2003). "Gene-environment interactions and etiology of common complex
619 disease." *Ann. Intern. Med.*, 139: 437-440.

620 Cutler DM, Glaeser E. (2005). "What explains differences in smoking, drinking and other
621 health-related behaviors?" *American Economic Review Papers and Proceedings*,
622 95: 238-242.

623 de Quervain DJ, Henke K, Aerni A, Coluccia D, Wollmer MA, Hock C, Nitsch RM,
624 Papassotiropoulos A. (2003). "A functional genetic variation of the 5-HT2a
625 receptor affects human memory." *Nature Neuroscience*, 6: 1141-1142.

626 de Quervain DJ, Papassotiropoulos A. (2006). "Identification of a genetic cluster
627 influencing memory performance and hippocampal activity in humans."
628 *Proceedings of the National Academy of Sciences*, 103: 4270-4274.

629 Deary IJ, Hamilton G, Hayward C, Whalley LJ, Powell J, Starr JM, Lovestone S. (2005a).
630 "Nicastrin gene polymorphisms, cognitive ability level and cognitive ageing."
631 *Neurosci. Lett.*, 373(2): 110-114.

632 Deary IJ, Harris SE, Fox HC, Hayward C, Wright AF, Starr JM, Whalley LJ. (2005b).
633 "KLOTHO genotype and cognitive ability in childhood and old age in the same
634 individuals." *Neurosci. Lett.*, 378(1): 22-27.

635 Dempster E, Touloupoulou T, McDonald C, Bramon E, Walshe M, Filbey F, Wickham H,
636 Sham PC, Murray RM, Collier DA. (2005). "Association between BDNF val66 met

637 genotype and episodic memory.” *Am. J. Med. Genet. B. Neuropsychiatr. Genet.*,
638 134(1): 73-75.

639 Devlin B & Roeder, K (1999) Genomic Control for Association Studies. *Biometrics*,
640 55:997-1004.

641 Dick DM, Agrawal A, Schuckit MA, Bierut L, Hinrichs A, Fox L, Mullaney J, Cloninger
642 CR, Hesselbrock V, Nurnberger JI Jr, Almasy L, Foroud T, Porjesz B, Edenberg H,
643 Begleiter H. Marital status, alcohol dependence, and GABRA2: evidence for gene-
644 environment correlation and interaction. *J Stud Alcohol*. 2006 Mar;67(2):185-94.

645 Dick DM, Aliev F, Bierut L, Goate A, Rice J, Hinrichs A, Bertelsen S, Wang JC, Dunn
646 G, Kuperman S, Schuckit M, Nurnberger J Jr, Porjesz B, Begleiter H, Kramer J,
647 Hesselbrock V. Linkage Analyses of IQ in the Collaborative Study on the Genetics
648 of Alcoholism (COGA) Sample. *Behav Genet*. 2006 Jan;36(1):77-86.

649 Dick DM, Aliev F, Kramer J, Wang JC, Hinrichs A, Bertelsen S, Kuperman S, Schuckit
650 M, Nurnberger Jr J, Edenberg HJ, Porjesz B, Begleiter H, Hesselbrock V, Goate A,
651 Bierut L. Association of CHRM2 with IQ: Converging Evidence for a Gene
652 Influencing Intelligence. *Behav Genet*. 2006.

653 DiLalla LF, Gottesman II. (1991). “Biological and genetic contributors to violence--
654 Widom's untold tale.” *Psychological Bulletin*, 109: 125-129.

655 Ding W, Lehrer SF, Rosenquist JN, Audrain-McGovern J. (2005). "The Impact of Health
656 on Academic Performance: New Evidence Using Genetic Markers." University of
657 Pennsylvania mimeo.

658 Dohmen T, Falk A, Huffman A, Sunde U, Schupp J, Wagner GG. (2005). "Individual risk
659 attitudes: Evidence from a large, representative, experimentally-validated survey."
660 IZA Discussion Paper No. 1730, September.

661 Donohoe G, Morris DW, Clarke S, McGhee KA, Schwaiger S, Nangle JM, Garavan H,
662 Robertson IH, Gill M, Corvin A. Variance in neurocognitive performance is
663 associated with dysbindin-1 in schizophrenia: A preliminary study.
664 Neuropsychologia. 2006.

665 Ebstein RP. The molecular genetic architecture of human personality: beyond self-report
666 questionnaires. Mol Psychiatry. 2006 May;11(5):427-45.

667 Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE, Goldman
668 D, Weinberger DR. (2001). "Effect of COMT Val108/158 Met genotype on frontal
669 lobe function and risk for schizophrenia." *Proceedings of the National Academy of*
670 *Sciences*, 98: 6917-6922.

671 Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E,
672 Gold B, Goldman D, Dean M, Lu B, Weinberger DR. (2003). "The BDNF
673 val66met polymorphism affects activity-dependent secretion of BDNF and human
674 memory and hippocampal function." *Cell*, 112(2): 257-269.

675 Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR, Mattay VS,
 676 Bertolino A, Hyde TM, Shannon-Weickert C, Akil M, Crook J, Vakkalanka RK,
 677 Balkissoon R, Gibbs RA, Kleinman JE, Weinberger DR. (2004). "Variation in
 678 GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia." *Proc.*
 679 *Natl. Acad. Sci. U.S.A.*, 101(34): 12604-12609.

680 Ellison-Wright Z, Heyman I, Frampton I, Rubia K, Chitnis X, Ellison-Wright I, Williams
 681 SC, Suckling J, Simmons A, Bullmore E. (2004). "Heterozygous PAX6 mutation,
 682 adult brain structure and fronto-striato-thalamic function in a human family." *Eur.*
 683 *J. Neurosci.* 19(6): 1505-1512.

684 Evans PD, Gilbert SL, Mekel-Bobrov N, Vallender EJ, Anderson JR, Vaez-Azizi LM,
 685 Tishkoff SA, Hudson RR, Lahn BT. (2005). "Microcephalin, a gene regulating
 686 brain size, continues to evolve adaptively in humans." *Science*, 309(5741): 1717-
 687 1720.

688 Evans PD, Vallender EJ, Lahn BT. Molecular evolution of the brain size regulator genes
 689 CDK5RAP2 and CENPJ. *Gene*. 2006 Jun 21;375:75-9.

690 Fallgatter AJ, Herrmann MJ, Hohoff C, Ehli AC, Jarczok TA, Freitag CM, Deckert J.
 691 DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in healthy
 692 individuals. *Neuropsychopharmacology*. 2006 Sep;31(9):2002-10.

693 Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P.
 694 (2005). "Molecular genetics of attention-deficit/hyperactivity disorder." *Biological*
 695 *Psychiatry*, 57: 1313–1323.

696 Fisher PJ, Turic D, Williams NM, McGuffin P, Asherson P, Ball D, Craig I, Eley T, Hill
697 L, Chorney K, Chorney MJ, Benbow CP, Lubinski D, Plomin R, Owen MJ. (1999).
698 “DNA pooling identifies QTLs on chromosome 4 for general cognitive ability in
699 children.” *Hum. Mol. Genet.*, 8(5): 915-922.

700 Fisher RA, Mackenzie WA. (1923). “Studies in crop variation. II. The manurial responses
701 of different potato varieties.” *Journal of Agricultural Science*, 13: 311-320.

702 Frederick S. (2005). “Cognitive reflection and decision making.” *Journal of Economic*
703 *Perspectives*, 19: 24-42.

704 Fuchs V. (1974). *Who Shall Live? Health, Economics and Social Choice*. New York:
705 Basic Books.

706 Fuchs V. (1982). “Time preference and health: An exploratory study.” In V. Fuchs (ed.),
707 *Economic Aspects of Health*. Chicago: University of Chicago Press, 93-120.

708 Garg A, Morduch J. (1998). “Sibling rivalry and the gender gap: Evidence from child
709 health outcomes in Ghana.” *J. Pop. Econ.*, 11: 471-493.

710 Gilbert SL, Dobyns WB, Lahn BT. (2005). “Genetic links between brain development
711 and brain evolution.” *Nat. Rev. Genet.*, 6(7): 581-590.

712 Glimcher PW, Dorris MC, Bayer HM. (2005). “Physiological utility theory and the
713 neuroeconomics of choice.” *Games Econ. Behav.*, 52(2): 213-256.

714 Glimcher PW, Rustichini A. (2004). "Neuroeconomics: The consilience of brain and
715 decision." *Science*, 306(5695): 447-452.

716 Goldberg TE, Weinberger DR. (2004). "Genes and the parsing of cognitive processes."
717 *Trends. Cogn. Sci.*, 8(7): 325-335.

718 Gosso MF, de Geus EJ, van Belzen MJ, Polderman TJ, Heutink P, Boomsma DI,
719 Posthuma D. The SNAP-25 gene is associated with cognitive ability: evidence from
720 a family-based study in two independent Dutch cohorts. *Mol Psychiatry*. 2006
721 Sep; 11(9):878-86.

722 Gosso MF, van Belzen M, de Geus EJ, Polderman JC, Heutink P, Boomsma DI,
723 Posthuma D. Association between the CHRM2 gene and intelligence in a sample of
724 304 Dutch families. *Genes Brain Behav*. 2006 Nov; 5(8):577-84.

725 Gray JR., Chabris CF, Braver TS. (2003). "Neural mechanisms of general fluid
726 intelligence." *Nature Neuroscience*, 6: 316-322.

727 Greenwood PM, Fossella JA, Parasuraman R. (2005). "Specificity of the effect of a
728 nicotinic receptor polymorphism on individual differences in visuospatial
729 attention." *J. Cogn. Neurosci*. 17(10): 1611-1620.

730 Hallmayer JF, Kalaydjieva L, Badcock J, Dragovic M, Howell S, Michie PT, Rock D,
731 Vile D, Williams R, Corder EH, Hollingsworth K, Jablensky A. (2005). "Genetic
732 evidence for a distinct subtype of schizophrenia characterized by pervasive
733 cognitive deficit." *American Journal of Human Genetics*, 77: 468-476.

734 Handoko HY, Nancarrow DJ, Mowry BJ, McGrath JJ. (2006). "Polymorphisms in the
735 vitamin D receptor and their associations with risk of schizophrenia and selected
736 anthropometric measures." *Am. J. Hum. Biol.*, 18(3): 415-417.

737 Hansell NK, James MR, Duffy DL, Birley AJ, Luciano M, Geffen GM, Wright MJ,
738 Montgomery GW, Martin NG. Effect of the BDNF V166M polymorphism on
739 working memory in healthy adolescents. *Genes Brain Behav.* 2006.

740 Hariri A.R, Brown S.M., Williamson D.E., Flory J.D., de Wit H., and Manuck S.B.
741 (2006) "Preference for Immediate over Delayed Rewards Is Associated with
742 Magnitude of Ventral Striatal Activity" *J. Neurosci.* 26 13213-13217.

743 Hariri AR, Mattay VS, Tessitore A, Kolachana B, Fera F, Goldman D, Egan MF,
744 Weinberger DR. (2002). "Serotonin transporter genetic variation and the response
745 of the human amygdala." *Science*, 297(5580): 400-403.

746 Harris SE, Fox H, Wright AF, Hayward C, Starr JM, Whalley LJ, Deary IJ. The brain-
747 derived neurotrophic factor Val66Met polymorphism is associated with age-related
748 change in reasoning skills. *Mol Psychiatry.* 2006 May;11(5):505-13.

749 Harris, TB, Launer LJ, Eiriksdottir G, Kjartansson O, Jonsson PV, Sigurdsson, G,
750 Thorgeirsson G, Aspelund T, Garcia ME, Cotch MF, Hoffman HJ, Gudnason V,
751 for the Age, Gene/Environment Susceptibility -Reykjavik Study Investigators
752 (2007). "Age, Gene/Environment Susceptibility -Reykjavik Study:
753 Multidisciplinary Applied Phenomics." *American Journal of Epidemiology*, in
754 press.

755 Hu X, Hicks CW, He W, Wong P, Macklin WB, Trapp BD, Yan R. Bace1 modulates
 756 myelination in the central and peripheral nervous system. *Nat Neurosci.* 2006
 757 Dec;9(12):1520-5.

758 Iidaka T, Ozaki N, Matsumoto A, Nogawa J, Kinoshita Y, Suzuki T, Iwata N, Yamamoto
 759 Y, Okada T, Sadato N. (2005). "A variant C178T in the regulatory region of the
 760 serotonin receptor gene HTR3A modulates neural activation in the human
 761 amygdala." *J. Neurosci.*, 25(27): 6460-6466.

762 Jacobsen LK, Pugh KR, Mencl WE, Gelernter J. C957T polymorphism of the dopamine
 763 D2 receptor gene modulates the effect of nicotine on working memory performance
 764 and cortical processing efficiency. *Psychopharmacology (Berl)*. 2006.

765 Jang KL, Vernon PA, Livesley WJ. (2000). "Personality disorder traits, family
 766 environment, and alcohol misuse: a multivariate behavioural genetic analysis."
 767 *Addiction*, 95: 873–888.

768 Jirtle RL. (2005). "Biological consequences of divergent evolution of M6P/IGF2R
 769 imprinting." Presented at the Environmental Epigenomics, Imprinting and Disease
 770 Susceptibility conference, Durham, NC, 2-4 November.

771 Kachiwala SJ, Harris SE, Wright AF, Hayward C, Starr JM, Whalley LJ, Deary IJ.
 772 (2005). "Genetic influences on oxidative stress and their association with normal
 773 cognitive ageing." *Neurosci. Lett.*, 386(2): 116-120.

774 Kendler K, Eaves L. (1986). "Models for the joint effect of genotype and environment on
 775 liability to psychiatric diseases." *American Journal of Psychiatry*, 143: 279-289.

776 Kimball MS, Sahm C, Shapiro MD. (2006). "Using survey-based risk tolerance."

777 Submitted for publication.

778 Kirby KN, Petry NM. (2004). "Heroin and cocaine abusers have higher discount rates for

779 delayed rewards than alcoholics or non-drug-using controls." *Addiction*, 99: 461-

780 471.

781 Kirby KN, Petry NM, Bickel WK. (1999). "Heroin addicts have higher discount rates for

782 delayed rewards than non-drug-using controls." *J. Exp. Psych.*, 128(1):78-87.

Formatted: English (U.S.)

783 Kovalchik S, Camerer CF, Grether DM, Plott CR, Allman JM. "Aging and decision

784 making: A broad comparative study of decision behavior in neurologically healthy

785 elderly and young individuals." Caltech manuscript, 2003.

786 Kravitz HM, Meyer PM, Seeman TE, Greendale GA, Sowers MR. Cognitive functioning

787 and sex steroid hormone gene polymorphisms in women at midlife. *Am J Med.*

788 2006 Sep;119(9 Suppl 1):S94-S102.

789 Laurin N, Misener VL, Crosbie J, Ickowicz A, Pathare T, Roberts W, Malone M,

790 Tannock R, Schachar R, Kennedy JL, Barr CL. (2005). "Association of the calcyon

791 gene (DRD1IP) with attention deficit/hyperactivity disorder." *Molecular*

792 *Psychiatry*, 10: 1117-1125.

793 Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, Drebing C, Berger R, Venn

794 D, Sirota P, Zerbe G, Olincy A, Ross RG, Adler LE, Freedman R. (2002).

795 "Association of promoter variants in the alpha7 nicotinic acetylcholine receptor

796 subunit gene with an inhibitory deficit found in schizophrenia.” *Arch. Gen.*
797 *Psychiatry.*, 59(12): 1085-1096.

798 Li Y, Hollingworth P, Moore P, Foy C, Archer N, Powell J, Nowotny P, Holmans P,
799 O'Donovan M, Tacey K, Doil L, van Luchene R, Garcia V, Rowland C, Lau K,
800 Cantanese J, Sninsky J, Hardy J, Thal L, Morris JC, Goate A, Lovestone S, Owen
801 M, Williams J, Grupe A. Genetic association of the APP binding protein 2 gene
802 (APBB2) with late onset Alzheimer disease. *Hum Mutat.* 2005 Mar;25(3):270-7.

803 Lichtenstein, P., Holm, N.V., Verkasalo, P.K., Iliadou, A., Kaprio, J., Koskenvuo, M.,
804 Pukkala, E., Skytthe, A., and Hemminki, K. (2000) “ Environmental and Heritable
805 Factors in the Causation of Cancer — Analyses of Cohorts of Twins from Sweden,
806 Denmark, and Finland” *New England Journal of Medicine* 343: 78-85.

807 Luciano, M., Lind, P., Wright, M., Duffy, D., Wainwright, M., Montgomery, G., &
808 Martin, N. (2006). Candidate genes for human brain evolution: Do they relate to
809 head size and cognitive ability? Presented at the International Congress of Human
810 Genetics, Brisbane, Australia, 6–10 August.

811 Luciano M, Wright MJ, Duffy DL, Wainwright MA, Zhu G, Evans DM, Geffen GM,
812 Montgomery GW, Martin NG. (2006). “Genome-wide Scan of IQ Finds Significant
813 Linkage to a Quantitative Trait Locus on 2q.” *Behav. Genet.*, 36(1): 45-55.

814 MacDonald SD, Perkins SL, Jodouin MLT, Walker MC. (2002). “Folate levels in
815 pregnant women who smoke: an important gene/environment interaction.” *Am. J.*
816 *Obstet. Gynecol.*, 187: 620-625.

817 MacKay TF. (2001). "The genetic architecture of quantitative traits." *Annu. Rev. Genet.*,
818 35: 303-339.

819 McClure, SM, Laibson DI, Loewenstein G, Cohen JD. (2004). "Separate neural systems
820 value immediate and delayed monetary rewards." *Science*, 306: 503–507.

821 McDaniel, MA. (2005). "Big-brained people are smarter: A meta-analysis of the
822 relationship between in vivo brain volume and intelligence." *Intelligence*, 33: 337–
823 346.

824 Mekel-Bobrov N, Gilbert SL, Evans PD, Vallender EJ, Anderson JR, Hudson RR,
825 Tishkoff SA, Lahn BT. (2005). "Ongoing adaptive evolution of ASPM, a brain size
826 determinant in Homo sapiens." *Science*, 309(5741): 1720-1722.

827 Meyer-Lindenberg A, Nichols T, Callicott JH, Ding J, Kolachana B, Buckholtz J, Mattay
828 VS, Egan M, Weinberger DR. Impact of complex genetic variation in COMT on
829 human brain function. *Mol Psychiatry*. 2006 Sep;11(9):867-77, 797.

830 Miller P, Mulvey C, Martin N. (2001). "Genetic and environmental contributions to
831 educational attainment in Australia." *Economics of Education Review*, 20: 211-224.

832 Mucci LA, Wedren S, Tamimi RM, Trichopoulos D, Adami H-O. (2001). "The role of
833 gene-environment interaction in the aetiology of human cancer: examples from
834 cancers of the large bowel, lung and breast." *Journal of Internal Medicine*, 249(6):
835 519-524.

836 Munafo MR, Clark TG, Moore LR, Payne E, Walton R, Flint J. Genetic polymorphisms
837 and personality in healthy adults: a systematic review and meta-analysis. *Mol*
838 *Psychiatry*. 2003 May;8(5):471-84.

839 Nelson E., and Cloninger C.R. (1997) "Exploring the TPQ as a possible predictor of
840 antidepressant response to nefazodone in a large multi-site study." *J. Affect.*
841 *Disorder* 44(2-3):197-200.

842 Olin D, MacMurray J, Comings DE. (2005). "Risk of late-onset Alzheimer's disease
843 associated with BDNF C270T polymorphism." *Neurosci. Lett.*, 381(3): 275-278.

844 Owen MJ, Craddock N, O'Donovan MC. (2005). "Schizophrenia: genes at last?" *Trends*
845 *Genet.*, 21(9): 518-525.

846 Papassotiropoulos A, Henke K, Aerni A, Coluccia D, Garcia E, Wollmer MA, Huynh
847 KD, Monsch AU, Stahelin HB, Hock C, Nitsch RM, de Quervain DJ. (2005a).
848 "Age-dependent effects of the 5-hydroxytryptamine-2a-receptor polymorphism
849 (His452Tyr) on human memory." *Neuroreport*, 16(8): 839-842.

850 Papassotiropoulos A, Wollmer MA, Aguzzi A, Hock C, Nitsch RM, de Quervain DJ.
851 (2005b). "The prion gene is associated with human long-term memory." *Hum. Mol.*
852 *Genet.*, 14(15): 2241-2246.

853 Papassotiropoulos, A., et al. (2006). Common Kibra alleles are associated with human
854 memory performance. *Science*, 314, 475–478.

855 Parasuraman R, Greenwood PM, Kumar R, Fossella J. (2005). "Beyond heritability:
856 Neurotransmitter genes differentially modulate visuospatial attention and working
857 memory." *Psychological Science*, 16: 200-207.

858 Payton A. (2006). "Investigating cognitive genetics and its implications for the treatment
859 of cognitive deficit." *Genes Brain Behav.*, 5(Suppl. 1) :44-53.

860 Payton A, Holland F, Diggle P, Rabbitt P, Horan M, Davidson Y, Gibbons L,
861 Worthington J, Ollier WE, Pendleton N. (2003). "Cathepsin D exon 2
862 polymorphism associated with general intelligence in a healthy older population."
863 *Mol. Psychiatry.*, 8(1): 14-18.

864 Payton A, Gibbons L, Davidson Y, Ollier W, Rabbitt P, Worthington J, Pickles A,
865 Pendleton N, Horan M. (2005). "Influence of serotonin transporter gene
866 polymorphisms on cognitive decline and cognitive abilities in a nondemented
867 elderly population." *Mol. Psychiatry.*, 10(12):1133-1139.

868 Payton A, van den Boogerd E, Davidson Y, Gibbons L, Ollier W, Rabbitt P, Worthington
869 J, Horan M, Pendleton N. (2006). "Influence and interactions of cathepsin D, HLA-
870 DRB1 and APOE on cognitive abilities in an older non-demented population."
871 *Genes Brain Behav.*, 5(Suppl. 1): 23-31.

872 Persico N, Postlewaite A, Silverman D. (2004) "The Effect of Adolescent Experience on
873 Labor Market Outcomes: The Case of Height." *Journal of Political Economy*, 112:
874 1019-1053.

875 Petry NM, Casarella T. (1999). "Excessive discounting of delayed rewards in substance
876 abusers with gambling problems." *Drug and Alcohol Dep.*, 56(1-2): 25-32.

877 Piluso G, Mirabella M, Ricci E, Belsito A, Abbondanza C, Servidei S, Puca AA, Tonalì
878 P, Puca GA, Nigro V. (2000). "Gamma1- and gamma2-syntrophins, two novel
879 dystrophin-binding proteins localized in neuronal cells." *Journal of Biological*
880 *Chemistry*, 275: 15851-15860.

881 Plomin R. (1999). "Genetics and general cognitive ability." *Nature*, 402 (Supplement):
882 C25-C29.

883 Plomin R, Bergeman CS. (1991). "The nature of nurture: genetic influence on
884 environmental measures." *Behavioral and Brain Sciences*, 14(3): 373-386.

885 Plomin R, Kennedy JK, Craig IW. (in press). "The quest for quantitative trait loci
886 associated with intelligence." *Intelligence*.

887 Plomin R, Turic DM, Hill L, Turic DE, Stephens M, Williams J, Owen MJ, O'Donovan
888 MC. (2004). "A functional polymorphism in the succinate-semialdehyde
889 dehydrogenase (aldehyde dehydrogenase 5 family, member A1) gene is associated
890 with cognitive ability." *Mol. Psychiatry*, 9(6): 582-586.

891 Porteous DJ, Thomson P, Brandon NJ, Millar JK. The genetics and biology of DISC1--an
892 emerging role in psychosis and cognition. *Biol Psychiatry*. 2006 Jul 15;60(2):123-31.

893 Posthuma D, Luciano M, Geus EJ, Wright MJ, Slagboom PE, Montgomery GW,
894 Boomsma DI, Martin NG. (2005). "A genome-wide scan for intelligence identifies
895 quantitative trait loci on 2q and 6p." *Am. J. Hum. Genet.*, 77(2): 318-326.

896 Pritchard JK, Stephens M & Donnelly PJ (2000) Inference of population structure using
897 multilocus genotype data. *Genetics* 155: 945-959.

898 Purcell S, Koenen KC. (2005). "Environmental mediation and the twin design." *Behavior*
899 *Genetics*, 35(4): 491-498.

900 Reif A, Herterich S, Strobel A, Ehli AC, Saur D, Jacob CP, Wienker T, Topner T,
901 Fritzen S, Walter U, Schmitt A, Fallgatter AJ, Lesch KP. A neuronal nitric oxide
902 synthase (NOS-I) haplotype associated with schizophrenia modifies prefrontal
903 cortex function. *Mol Psychiatry*. 2006 Mar;11(3):286-300.

904 Rosenberg S, Templeton AR, Feigin PD, Lancet D, Beckmann JS, Selig S, Hamer DH,
905 Skorecki K. The association of DNA sequence variation at the MAOA genetic locus
906 with quantitative behavioural traits in normal males. *Hum Genet*. 2006
907 Nov;120(4):447-59.

908 Rubia K, Lee F, Cleare AJ, Tunstall N, Fu CH, Brammer M, McGuire P. (2005).
909 "Tryptophan depletion reduces right inferior prefrontal activation during response
910 inhibition in fast, event-related fMRI." *Psychopharmacology*, 179: 791-803.

911 Rujescu D, Meisenzahl EM, Giegling I, Kirner A, Leinsinger G, Hegerl U, Hahn K,
912 Moller HJ. (2002). "Methionine homozygosity at codon 129 in the prion protein is
913 associated with white matter reduction and enlargement of CSF compartments in
914 healthy volunteers and schizophrenic patients." *Neuroimage*, 15(1): 200-206.

915 Rujescu D, Hartmann AM, Gonnermann C, Moller HJ, Giegling I. (2003). "M129V
 916 variation in the prion protein may influence cognitive performance." *Mol.*
 917 *Psychiatry*, 8(11):937-941.

918 Rujescu D, Meisenzahl EM, Krejcová S, Giegling I, Zetzsche T, Reiser M, Born CM,
 919 Moller HJ, Veske A, Gal A, Finckh U. Plexin B3 is genetically associated with
 920 verbal performance and white matter volume in human brain. *Mol Psychiatry*. 2006.

921 Shapiro JM. (2005). "Is there a daily discount rate? Evidence from the food stamp
 922 nutrition cycle." *J. Pub. Econ.*, 89(2): 303-325.

923 Shimokata H, Ando F, Niino N, Miyasaka K, Funakoshi A. (2005). "Cholecystokinin A
 924 receptor gene promoter polymorphism and intelligence." *Ann. Epidemiol.*, 15(3):
 925 196-201.

926 Siintola E, Partanen S, Stromme P, Haapanen A, Haltia M, Maehlen J, Lehesjoki AE,
 927 Tyynela J. Cathepsin D deficiency underlies congenital human neuronal ceroid-
 928 lipofuscinosis. *Brain*. 2006 Jun;129(Pt 6):1438-45.

929 Small BJ, Rosnick CB, Fratiglioni L, Backman L. (2004). "Apolipoprotein E and
 930 cognitive performance: a meta-analysis." *Psychol. Aging*, 19(4): 592-600.

931 Smith A. (1776). *An Inquiry into the Nature and Causes of the Wealth of Nations*,
 932 *Volumes I and II*. R.H. Campbell and A.S. Skinner, eds. Indianapolis: Liberty Fund.

933 Spielman RS, McGinnis RE, Ewens WJ (1993) Transmission test for linkage
 934 disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus
 935 (IDDM). *Am J Hum Genet.* 52(3):506-16.

936 Stigler GJ. (1971). "The theory of economic regulation." *Bell Journal of Economics*, 2(1):
 937 3-21.

938 Tang Y, Buxbaum SG, Waldman I, Anderson GM, Zabetian CP, Kohnke MD, Cubells
 939 JF. (2006). "A Single Nucleotide Polymorphism at DBH, Possibly Associated with
 940 Attention-Deficit/Hyperactivity Disorder, Associates with Lower Plasma Dopamine
 941 beta-Hydroxylase Activity and is in Linkage Disequilibrium with Two Putative
 942 Functional Single Nucleotide Polymorphisms." *Biol Psychiatry*, April 7.

943 Taubman P. (1976). "The determinants of earnings: Genetics, family, and other
 944 environments: A study of white male twins." *American Economic Review*, 66: 858-
 945 870.

946 Thomson PA, Harris SE, Starr JM, Whalley LJ, Porteous DJ, Deary IJ. (2005).
 947 "Association between genotype at an exonic SNP in DISC1 and normal cognitive
 948 aging." *Neurosci. Lett.*, 389(1): 41-45.

949 Voight BF, Kudaravalli S, Wen X, Pritchard JK. (2006). "A map of recent positive
 950 selection in the human genome." *PLoS Biol.*, 4(3):e72.

951 Wahlsten D. (1990). "Insensitivity of the analysis of variance to heredity-environment
 952 interaction." *Behavioral and Brain Sciences*, 13: 109-161.

953 Walderhaug E, Lunde H, Nordvik JE, Landro NI, Refsum H, Magnusson A. (2002).
 954 “Lowering of serotonin by rapid tryptophan depletion increases impulsiveness in
 955 normal individuals.” *Psychopharmacology*, 164: 385-391.

956 Wang ET, Kodama G, Baldi P, Moyzis RK. Global landscape of recent inferred
 957 Darwinian selection for *Homo sapiens*. *Proc Natl Acad Sci U S A*. 2006 Jan
 958 3;103(1):135-40.

959 Wang YQ, Qian YP, Yang S, Shi H, Liao CH, Zheng HK, Wang J, Lin AA, Cavalli-
 960 Sforza LL, Underhill PA, Chakraborty R, Jin L, Su B. (2005). “Accelerated
 961 evolution of the pituitary adenylate cyclase-activating polypeptide precursor gene
 962 during human origin.” *Genetics*, 170(2): 801-806.

963 Widom, CS. (1989). “The cycle of violence.” *Science*, 244(4901): 160-166.

964 Woods CG, Bond J, Enard W. (2005). “Autosomal recessive primary microcephaly
 965 (MCPH): A review of clinical, molecular, and evolutionary findings.” *American*
 966 *Journal of Human Genetics*, 76: 717-728.

967 Woods RP, Freimer NB, De Young JA, Fears SC, Sicotte NL, Service SK, Valentino DJ,
 968 Toga AW, Mazziotta JC. Normal variants of Microcephalin and ASPM do not account
 969 for brain size variability. *Hum Mol Genet*. 2006 Jun 15;15(12):2025-9.

970 Wu S, Jia M, Ruan Y, Liu J, Guo Y, Shuang M, Gong X, Zhang Y, Yang X, Zhang D.
 971 (2005). “Positive association of the oxytocin receptor gene (OXTR) with autism in
 972 the Chinese Han population.” *Biol. Psychiatry*, 58(1): 74-77.

973 Ylisaukko-Oja T, Alarcon M, Cantor RM, Auranen M, Vanhala R, Kempas E, von Wendt
974 L, Jarvela I, Geschwind DH, Peltonen L. (2005). "Search for autism loci by
975 combined analysis of Autism Genetic Resource Exchange and Finnish families."
976 *Ann. Neurol.*, 59(1): 145-155.

977 **Figure Captions**

978 FIGURE 1: Percentage of respondents in the Icelandic data who have a second job, by
979 gender and age. Source: Author's calculations.

980 FIGURE 2: Distribution of working hours in the Icelandic data, by gender and age.

981 Source: Author's calculations.

982 **TABLE 1 Measured Phenotypes in the Icelandic Data**
983

Measured phenotypes	Reykjavik Study 1967–1991	Older Persons Exam 1991–1996	AGES- Reykjavik 2002–2006
Distal economic phenotypes			
Number of jobs and hours worked (labor supply)	X	X	
Attributes of house/apartment (housing wealth)	X	X	
Occupational history (human capital accumulation)	X	X	X
Years of education (human capital accumulation)	X	X	X
Social networks (social capital accumulation)		X	X
Proximal decision-making phenotypes			
Smoking frequency (impulsivity)	X	X	X
Drinking frequency (impulsivity)		X	X
Exercise frequency (impulsivity)	X	X	X
Eating habits (impulsivity)		X	X
Health conscientiousness (impulsivity)	X	X	
Long-term memory (general cognitive ability)			X
Speed of processing (general cognitive ability)		X	X
Working memory (general cognitive ability)			X
MRI of the brain (general cognitive ability)			X

984 NOTES: This table displays phenotypic data already collected. For the next wave of the
985 AGES-Reykjavik study, we plan to add additional distal phenotypes (wealth and income)
986 and proximal phenotypes (experimental measures of impulsivity and risk-aversion). The
987 cognitive SNP panel will be administered to participants in the AGES-Reykjavik study.
988 In addition to the AGES-Reykjavik questionnaire, participants in the AGES-Reykjavik
989 study have answered the Reykjavik study questionnaire once, twice, or six times during
990 1967–1991. The Older Persons Exam was administered to those aged 70 and older as of
991 1991.

TABLE 2. Genes that are candidates for inclusion in a panel of SNPs for association studies with cognitive, neural, and economic phenotypes, with notes on possible mechanisms mediating genetic influences on these phenotypes (or other reasons for including the gene). Both known or suspected functional SNPs in these genes, as well as tagging SNPs from the HapMap, would be used. Names and genomic positions are taken from OMIM or the UCSC Genome Browser. Genes marked with an asterisk (*) have known or probable functional alleles that are *not* SNPs. Citations given for each gene are meant to be representative of the suggestive evidence in the literature (through 2006), not exhaustive lists of relevant publications on the gene.

Gene	Position	Description and references
<i>Dopamine (DA) System</i>		
TH	11p15.5	Tyrosine hydroxylase
DDC	7p12.2	Dopa decarboxylase
VMAT1	8p21.3	Vesicular monoamine transporter 1
VMAT2	10q25.3	Vesicular monoamine transporter 2
DRD1	5q35.1	Dopamine receptor 1 ADHD (Bobb et al., 2005)
DRD2	11q23	Dopamine receptor 2 Neural activation during working memory (Jacobsen et al., 2006) DRD2 binding in striatum (Hirvonen et al., 2004)
DRD3	3q13.3	Dopamine receptor 3
DRD4*	11p15.5	Dopamine receptor 4 ADHD (Faraone et al., 2005)
DRD5	4p16.1	Dopamine receptor 5 ADHD (Faraone et al., 2005)
CALCYON	10q26.3	Calcyon (DRD1 interacting protein) ADHD (Laurin et al., 2005)
DAT1*	5p15.3	Dopamine transporter ADHD (Faraone et al., 2005)
COMT	22q11.2	Catechol-o-methyltransferase Frontal lobe, executive function (Egan et al., 2001; Meyer-Lindberg et al., 2006)
MAOA*	Xp11.23	Monoamine oxidase A NEO personality traits (Rosenberg et al., 2006); aggression GxE interaction (Caspi et al., 2002)
MAOB	Xp11.23	Monoamine oxidase B


1045			
1046	DBH	9q34.2	Dopamine beta hydroxylase
1047			ADHD (Faraone et al., 2005)
1048			
1049			
1050	<i>Serotonin (5-HT) System</i>		
1051			
1052	TPH1	11p15.3	Tryptophan hydroxylase 1
1053			
1054	TPH2	12q21.1	Tryptophan hydroxylase 2
1055			
1056	HTR1A		Serotonin receptor 1A
1057			
1058	HTR1B	6q14.1	Serotonin receptor 1B
1059			ADHD (Faraone et al., 2005)
1060			
1061	HTR2A	13q14.2	Serotonin receptor 2A
1062			Explicit memory (de Quervain et al., 2003; Papassotiropoulos et al.,
1063			2005; Reynolds et al., 2006)
1064			
1065	HTR3A	11q23.1	Serotonin receptor 3A
1066			Amygdala & frontal lobe function (Iidaka et al., 2005)
1067			
1068	HTT*	17q11.1	Serotonin transporter
1069			Amygdala function (Hariri et al., 2003)
1070			ADHD (Faraone et al., 2005)
1071			Cognitive aging (Payton et al., 2005)
1072			Under selection in CEU and ASN populations (Voight et al., 2006)
1073			
1074			
1075	<i>Genes Reported to be Associated with General Cognitive Ability</i>		
1076	(reviewed by Payton, 2006; Plomin et al., in press)		
1077			
1078	CBS	21q22.3	Cystathionine beta-synthase
1079			IQ (Barbaux et al., 2000)
1080			
1081	CCKAR	4p15.2	Cholecystokinin A receptor
1082			IQ (Shimokata et al., 2005)
1083			
1084	CHRM2	7q33	Muscarinic cholinergic receptor 2
1085			IQ (Comings et al., 2003; Gosso et al., 2006)
1086			Performance IQ (Dick, Aliev, Kramer et al., 2006)
1087			
1088	CTSD	11p15.5	Cathepsin D
1089			Mental retardation & microcephaly caused by mutation (Siintola et al.,
1090			2006)
1091			IQ (Payton et al., 2003, 2006)
1092			
1093	IGF2R	6q25.3	Insulin-like growth factor 2 receptor
1094			IQ (Chorney et al., 1998; Jirtle, 2005)
1095			
1096	KLOTHO	13q13.1	Klotho
1097			IQ (Deary et al., 2005b)
1098			
1099	MSX1	4p16.2	Muscle segment homeobox, drosophila, homolog of, 1
1100			IQ (Fisher et al., 1999)

1101			
1102	NCSTN	1q23.2	Nicastrin
1103			IQ (Deary et al., 2005a)
1104			AD (Bertram et al., 2007)
1105			
1106	PLXNB3	Xq28	Plexin B3
1107			Vocabulary, white matter (Rujescu et al., 2006)
1108			
1109	PRNP	20p13	Prion protein
1110			IQ (Rujescu et al., 2003; Kachiwala et al., 2005)
1111			Brain structure (Rujescu et al., 2002)
1112			Long-term memory (Papassotiropoulos et al., 2005b)
1113			AD (Bertram et al., 2007)
1114			
1115	RECQL2	8p12	RECQ protein-like 2
1116			Cognitive composite in LSADT (Bendixen et al., 2004)
1117			
1118	SSADH	6p22.2	Succinate semi-aldehyde dehydrogenase
1119			IQ (Plomin et al., 2004)
1120			IQ linkage peak on chr6 is near this gene (Posthuma et al., 2005)
1121			Recent positive selection (Blasi et al., 2006)
1122			
1123			
1124	<i>Candidate Genes Near Linkage Peaks in Studies of IQ</i>		
1125	(Posthuma et al., 2005; Luciano et al., 2006; Hallmayer et al., 2005; Dick, Aliev, Beirut et al., 2006)		
1126			
1127	NR4A2	2q24.1	Nuclear receptor subfamily 4, group A, member 2
1128			
1129	SLC25A12	2q31.1	Solute carrier family 25, member 12
1130			
1131	SCN1A	2q24.3	Sodium channel, neuronal type 1, alpha subunit
1132			
1133	SCN2A	2q24.3	Sodium channel, neuronal type 2, alpha subunit
1134			
1135	TBR1	2q24.2	T-box, brain, 1
1136			
1137	SCN3A	2q24.3	Sodium channel, neuronal type 3, alpha subunit
1138			
1139	KCNH7	2q24.2	Potassium channel, voltage-gated, subfamily H, member 7
1140			
1141	GAD1	2q31.1	Gluatamate decarboxylase 1
1142			
1143	HOXD1	2q31.1	Homeobox D1
1144			
1145	CHN1	2q31.1	Chimerin 1
1146			
1147	RAPGEF4	2q31.1	RAP guanine nucleotide exchange factor
1148			
1149	NOSTRIN	2q24.3	Nitric oxide synthase trafficker
1150			
1151	BBS5	2q31.1	BBS5 gene
1152			
1153	DLX1	2q31.1	Distal-less homeobox 1
1154			
1155	DLX2	2q31.1	Distal-less homeobox 2
1156			

1157	KIF13A	6p22.3	Kinesin family member 13A
1158			
1159	NQO2	6p25.2	NAD(P)H dehydrogenase, quinone 2
1160			
1161	RANBP9	6p23	RAN-binding protein 9
1162			
1163	PNR	6q23.2	Trace amine-associated receptor 5 (“putative neurotransmitter receptor”)
1164			
1165	NRN1	6p25.1	Neuritin 1
1166			
1167	S100B	21q22.3	S100 calcium-binding protein, beta
1168			
1169			
1170	<i>Genes Associated with Memory Ability</i>		
1171			
1172	<u>de Quervain & Papassotiropoulos, 2006</u>		
1173			
1174	ADCY8	8q24.2	Adenylate cyclase 8
1175			
1176	CAMK2G	10q22	Calcium/calmodulin-dependent protein kinase 2 gamma
1177			
1178	GRIN2A	16p13	Ionotropic glutamate receptor, NMDA subunit 2A
1179			
1180	GRIN2B	12p12	Ionotropic glutamate receptor, NMDA subunit 2B
1181			
1182	GRM3	7q21.1	Metabotropic glutamate receptor 3
1183			Frontal & hippocampal function (Egan et al., 2004)
1184			
1185	PRKCA	17q22–23.2	Protein kinase C, alpha
1186			
1187	PRKACG	9q13	Protein kinase, cAMP-dependent, catalytic, gamma
1188			
1189	<u>Papassotiropoulos et al., 2006</u>		
1190			
1191	KIBRA	5q35.1	Kidney and brain expressed protein
1192			
1193	CLSTN2	3q23	Calsyntenin 2
1194			
1195	<u>Kravitz et al., 2006</u>		
1196			
1197	ESR1	6q25.1	Estrogen receptor 1
1198			AD (Bertram et al., 2007)
1199			
1200	HSD17B1	17q21.31	Hydroxysteroid (17-beta) dehydrogenase 1
1201			
1202			
1203	<i>Genes Associated with Schizophrenia (SZ)</i>		
1204	(reviewed by Norton et al., 2006; Owen et al., 2005)		
1205			
1206	AKT1	14q32.3	V-AKT murine thymoma viral oncogene homolog 1
1207			
1208	DAOA	13q34	D-amino acid oxidase activator
1209			
1210	DISC1	1q42.1	Disrupted in schizophrenia 1
1211			Hippocampal structure and function (Callicott et al., 2005)
1212			Cognitive aging in women (Thomson et al., 2005)


1213			Cognitive performance in SZ (Burdick et al., 2005; reviewed by Porteous et al., 2006)
1214			
1215			
1216	DTNBP1	6p22.3	Dystrobrevin-binding protein 1
1217			g in SZ & controls (Burdick et al., 2006)
1218			IQ (Posthuma et al., 2005): linkage peak on chr6 contains this gene
1219			PFC function (Fallgatter et al., 2006)
1220			Under selection in Europeans (Voight et al., 2006)
1221			
1222	NRG1	8p22	Neuregulin 1
1223			Premorbid IQ in high-risk SZ subjects (Hall et al., 2006)
1224			
1225	RGS4	1q23.3	Regulator of G-protein signaling 4
1226			Talkowski et al. (2006)
1227			
1228			
1229	<i>Genes Associated with Alzheimer's Disease (AD)</i>		
1230	(reviewd by Bertram et al., 2007; Bertram & Tanzi, 2004)		
1231			
1232	ACE	17q23	Angiotensin I-converting enzyme
1233			
1234	APOE	19q13.2	Apolipoprotein E
1235			Risk factor for AD, general cognitive function (Small et al., 2004)
1236			
1237	BACE1	11q23.3	Beta-site amyloid beta A4 precursor protein-cleaving enzyme 1
1238			Interacts w/ APOE (Bertram & Tanzi, 2004)
1239			Modulates myelination in mice (Hu et al., 2006)
1240			
1241	CHRNA2	1q21	Cholinergic receptor, neural nicotinic, beta polypeptide 2
1242			
1243	CST3	20p11.2	Cystatin 3
1244			
1245	GAPDH	19q13.1	Glyceraldehyde-3 phosphate dehydrogenase, spermatogenic
1246			
1247	IDE	10q23.33	Insulin-degrading enzyme 2
1248			Interacts w/ APOE (Bertram & Tanzi, 2004)
1249			
1250	MTHFR	1p36.3	Methylenetetrahydrofolate reductase
1251			
1252	PSEN1	14q24.3	Presenilin 1
1253			
1254	TF	3q21	Transferrin
1255			
1256	TFAM	10q21	Transcription factor A, mitochondrial
1257			
1258	TNF	6p21.3	Tumor necrosis factor
1259			
1260			
1261	<i>Genes Associated with Brain/Head Size</i>		
1262	(except for VDR, all have mutations causing microcephaly)		
1263			
1264	ASPM	1q31.3	Abnormal spindle-like, microcephaly-associated
1265			Under selection in humans (Mekel-Bobrov et al., 2005)
1266			Small effect on IQ subtests (Luciano et al., 2006)
1267			No significant effect on normal-range brain size (Woods et al., 2006)
1268			

1269	CDK5RAP2	9q33.2	CDK5 regulatory subunit associated protein 2
1270			Brain size (Woods et al., 2005; Evans et al., 2006)
1271			Reverse association w/ verbal IQ (Luciano et al., 2006)
1272			
1273	CENPJ	13q12.12	Centromeric protein J
1274			Brain size; under selection in CEU sample (Voight et al., 2006; cf. Evans et al., 2006)
1275			
1276			
1277	MCPH1	8p23.1	Microcephalin
1278			Under selection in humans (Evans et al., 2005)
1279			No significant effects on IQ subtests (Luciano et al., 2006), normal-range
1280			brain size (Woods et al., 2006)
1281			
1282	VDR	12q13.11	Vitamin D receptor
1283			Head size (Handoko et al., 2006), not associated with schizophrenia
1284			
1285			
1286	<i>Genes Associated with Miscellaneous Brain and Cognitive Functions</i>		
1287			
1288	BDNF	11p14.1	Brain-derived neurotrophic factor
1289			Memory, hippocampus (Egan et al., 2003; Dempster et al., 2005)
1290			Age-related cognitive decline (Harris et al., 2006)
1291			Not associated with working memory performance (Hansell et al., 2006)
1292			
1293	CHRNA4	20q13.2	Neuronal nicotinic cholinergic receptor alpha polypeptide 4
1294			Attentional function (Greenwood et al., 2005; Parasuraman et al., 2005)
1295			
1296	CHRNA7	15q13.3	Neuronal nicotinic cholinergic receptor alpha polypeptide 7
1297			Schizophrenia and auditory processing (Leonard et al., 2002)
1298			
1299	NET1	16q12.2	Norepinephrine transporter
1300			ADHD (Bobb et al., 2005)
1301			
1302	OXTR	3p26.2	Oxytocin receptor
1303			Trust; autism (Wu et al., 2005; Ylisaukko-Oja et al., 2005)
1304			
1305	PAX6	11p13	Paired box gene 6
1306			Development of executive function networks (Ellison-Wright et al., 2004)
1307			
1308	SNAP25	20p12.2	Synaptosomal-associated protein, 25-KD
1309			ADHD (Faraone et al., 2005)
1310			Performance IQ (Gosso et al., 2006)
1311			
1312	FADS2	11q12-q13	Fatty-acid desaturase 2
1313			ADHD (Brookes et al., 2006)
1314			
1315	NOS1	12q24	Neuronal nitric oxide synthase
1316			PFC function, schizophrenia (Reif et al., 2006)
1317			
1318	CETP	16q21	Cholesterol ester transfer protein
1319			Better MMSE performance in centenarians (Barzilai et al., 2006)
1320			



1321
1322
1323

FIGURE 1



1325
1326
1327

FIGURE 2